Medivation Announces Management Changes SAN FRANCISCO,

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Medivation Announces Management Changes

SAN FRANCISCO, CA--(Marketwired - Sep 29, 2015) -  Medivation, Inc. ( NASDAQ : MDVN ) today announced that Dr. Lynn Seely, its chief medical officer, plans to retire from her position effective October 15, 2015, after over ten years of service. She will continue as a consultant to Medivation for a period of six months, during which she will assist with the transition of her responsibilities. Mohammad Hirmand, M.D., who has been responsible for the XTANDI ® (enzalutamide) prostate cancer development program, including the pivotal clinical trials (AFFIRM and PREVAIL) which led to XTANDI's approval for metastatic castration-resistant prostate cancer, has been promoted to interim chief medical officer and will be considered for the permanent position of chief medical officer. 

"After more than a decade as Medivation's chief medical officer, Lynn has decided to retire from her position at Medivation. As one of the first members of the Medivation team, she has made a unique contribution to the development of XTANDI and the growth of the company," said David Hung, M.D., president and chief executive officer of Medivation. "Medivation and the community of prostate cancer patients owe her a huge debt of gratitude for her efforts, and we wish her every success in her next endeavors."

Dr. Hirmand joined Medivation as senior director, clinical development in August 2007 and most recently served as senior vice president of clinical development and operations. Over the past eight years, he has played an instrumental role in advancing Medivation's clinical trials, including those for enzalutamide, which led to the approval of XTANDI (enzalutamide) capsules for the treatment of metastatic castration-resistant prostate cancer. Before joining Medivation, he was a senior director of clinical development at Nuvelo, Inc. (now ARCA biopharma), where he led the clinical development department comprised of clinical operations, clinical data management and clinical sciences/medical monitor staff. Before that, he served as director of oncology development at SuperGen, Inc. (now Astex Pharmaceuticals, Inc) and as associate director of clinical research at Amgen, Inc. (formerly Tularik, Inc.), where he led clinical development efforts for Tularik's oncology trials. Early in his career, he was a clinical scientist and manager of market development and product evaluation at Theravance Biopharma, Inc. Dr. Hirmand holds a Bachelor of Arts degree from Cornell University. Dr. Hirmand received his M.D. from Harvard Medical School.

Separately, Medivation announced the addition of two new hires. Tom Templeman, Ph.D., has joined Medivation as senior vice president of pharmaceutical operations. Lily Yang has joined Medivation as vice president, finance and accounting and will serve as Medivation's principal accounting officer.

"Tom and Lily are great additions to our company and demonstrate our commitment to building a deep and world class management team. They bring us the leadership and experience in their respective fields that will keep Medivation at the forefront of growth and innovation in the biotech industry," said David Hung, M.D., president and chief executive officer of Medivation. "I am joined by all their colleagues in wishing them every success." 

With over 25 years of pharmaceutical experience, Dr. Templeman previously served as vice president of manufacturing, science and technology at Hospira, as senior vice president, integrated supply chain at Liquidia Technologies and in various leadership roles at Johnson & Johnson, where he worked for 13 years in a number of capacities, most recently as general manager of Centocor Biologics, LLC and head of the global biologics supply chain. Dr. Templeman holds a Bachelor of Science degree in Biology from the University of Santa Clara and a Ph.D. from Dartmouth College and was a National Institutes of Health postdoctoral fellow at Harvard University. 

Most recently, Ms. Yang served as vice president and corporate controller at Gilead Sciences, Inc. In her 12 years at Gilead, Ms. Yang led or worked in accounting, financial planning & analysis, SEC reporting, technical accounting, financial systems, strategic planning, Sarbanes-Oxley Act compliance and treasury. Previously, Ms. Yang was at General Electric and Arthur Andersen. Ms. Yang holds a Bachelor of Science degree in Accounting and Managerial Information Systems from Boston University and is a certified public accountant.

About Medivation Inc. Medivation, Inc. is a biopharmaceutical company focused on the development and commercialization of medically innovative therapies to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their families. For more information, please visit us at http://www.medivation.com

Contacts: Rick Bierly Chief Financial Officer (415) 543-3470 Anne Bowdidge Senior Director, Investor Relations (650) 218-6900

Scroll down for more posts ▼

Top 10 Most Recent News Articles

UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 394

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
EyePoint Lawsuit Puts DURAVYU Claims Under a Microscope

Updated Category News Views 55

Nothing makes biotech investors reach for the aspirin faster than a lawsuit centered on whether a drug worked as advertised. EyePoint, Inc. is facing a proposed federal securities class action alleging that the company overstated the effectiveness of DURAVYU and, by extension, its clinical, regulatory, and commercial prospects. That is a serious allegation, but it remains...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 137

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 410

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Cardiovalve's Three-Year Data Clears a Crucial EU Hurdle

Updated Category News Views 98

A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do...

Continue Reading
Build-A-Bear Lawsuit Notice Carries a Date Problem

Updated Category News Views 49

Something is badly out of sequence in the Build-A-Bear shareholder alert, and that matters before anybody gets carried away by the legal boilerplate. The notice says investors who bought NYSE: BBW securities from March 28, 2026 through August 26, 2026 may be covered by a proposed federal securities class action. It also says the lead-plaintiff deadline is January 19,...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 191

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 618

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
DKSH's Vietnam Oncology Pact Carries Real Promise, Risk

Updated Category News Views 52

A cancer-market announcement ought to make investors pause before they reach for a spreadsheet. Specialised Therapeutics and DKSH have signed an exclusive partnership to bring oncology therapies into Vietnam, and the human case is painfully clear: the country recorded an estimated 180,000 new cancer cases and more than 120,000 deaths annually in the 2022 GLOBOCAN data....

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 445

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading

Top 5 Most Recently Viewed Articles

Celebrating the Legacy of the Kashi Fair: A Cultural Journey

Updated Category News Views 387

The Kashi Fair: A Living Tribute to the Silk Road The Kashi Fair, also known as the Kashi-Central and South Asia Commodity Fair, has become an essential trade event, connecting cultures and economies while celebrating the essence of the historic Silk Road. For Pakistani businessman Muhammad Abbas, the Managing Director of Pakistan Northern Gems, this annual event in Kashi...

Continue Reading
Global Forum Focuses on Sustainable Future and Cooperation

Updated Category News Views 260

Global Leaders Gather to Discuss a Sustainable Future Under the theme "Collective Action for One Future", a significant forum took place in a vibrant city, bringing together over 130 leaders from various nations. This event marked the ninth edition of an esteemed international gathering focused on transformative issues affecting the worldwide landscape. For the first...

Continue Reading
Blue Onion Secures $10 Million to Enhance Financial Data Management

Updated Category News Views 294

Blue Onion Secures $10 Million Series A Funding In a significant advancement for financial data management, Blue Onion has successfully secured $10 million in a Series A funding round, led by Viola FinTech. This strategic investment aims to broaden Blue Onion's capabilities in delivering accurate and fully reconciled transaction-level data that CFOs can trust. With this...

Continue Reading
Lilly's Retatrutide Outshines Ozempic in Key Diabetes Trial

Updated Category News Views 120

Lilly's Breakthrough in Diabetes Treatment Eli Lilly's retatrutide is stirring up the diabetes treatment waters. The latest Phase 3 comparison to Ozempic's top dose reveals some surprising results. I'm not one to toss out kudos lightly, but this could be a genuine game-changer if things hold steady. A1C Reductions: A Close Look at the Numbers We’re staring down the...

Continue Reading
Investing in Houlihan Lokey: A Decade of Growth Insights

Updated Category News Views 176

Understanding the Investment Journey with Houlihan Lokey Houlihan Lokey (NYSE: HLI) has demonstrated remarkable performance over the past decade. This investment bank has outshined market averages, yielding an impressive annualized return of 22.61%. As of now, Houlihan Lokey boasts a significant market capitalization of $12.57 billion, showcasing its robust standing in...

Continue Reading